430 related articles for article (PubMed ID: 33596362)
1. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy.
Chong EA; Ruella M; Schuster SJ;
N Engl J Med; 2021 Feb; 384(7):673-674. PubMed ID: 33596362
[No Abstract] [Full Text] [Related]
2. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
3. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Chow VA; Shadman M; Gopal AK
Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
[TBL] [Abstract][Full Text] [Related]
4. CAR T cell therapy for B-cell lymphomas.
Chavez JC; Locke FL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
[TBL] [Abstract][Full Text] [Related]
5. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
Munshi PN; Ujjani C
Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
[TBL] [Abstract][Full Text] [Related]
6. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jäger U; Jaglowski S; Andreadis C; Westin JR; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Magenau JM; Holte H; Pantano S; Pacaud LB; Awasthi R; Chu J; Anak Ö; Salles G; Maziarz RT;
N Engl J Med; 2019 Jan; 380(1):45-56. PubMed ID: 30501490
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
Levin A; Shah NN
Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
[TBL] [Abstract][Full Text] [Related]
8. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
Reagan PM; Friedberg JW
Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
[TBL] [Abstract][Full Text] [Related]
9. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
Abbasi A; Peeke S; Shah N; Mustafa J; Khatun F; Lombardo A; Abreu M; Elkind R; Fehn K; de Castro A; Wang Y; Derman O; Nelson R; Uehlinger J; Gritsman K; Sica RA; Kornblum N; Mantzaris I; Shastri A; Janakiram M; Goldfinger M; Verma A; Braunschweig I; Bachier-Rodriguez L
J Hematol Oncol; 2020 Jan; 13(1):1. PubMed ID: 31900191
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
11. CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
Gideon J
Clin J Oncol Nurs; 2022 Nov; 26(6):597-601. PubMed ID: 36413724
[TBL] [Abstract][Full Text] [Related]
12. Late Events After CD-19 CAR-T Treatment.
Hossain NM; Nishimura MI
Biol Blood Marrow Transplant; 2020 Jan; 26(1):e1-e2. PubMed ID: 31669398
[No Abstract] [Full Text] [Related]
13. Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.
Hill BT; Roberts ZJ; Xue A; Rossi JM; Smith MR
Bone Marrow Transplant; 2020 Jun; 55(6):1184-1187. PubMed ID: 31471571
[No Abstract] [Full Text] [Related]
14. [Current status of diagnosis and treatment in diffuse large B-cell lymphoma].
Shimada K
Rinsho Ketsueki; 2021; 62(8):1077-1084. PubMed ID: 34497194
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy with cells.
Chong EA; Porter DL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):590-597. PubMed ID: 33275723
[TBL] [Abstract][Full Text] [Related]
16. The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
Nair R; Neelapu SS
Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399
[TBL] [Abstract][Full Text] [Related]
17. CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before.
Ghilardi G; Braendstrup P; Chong EA; Schuster SJ; Svoboda J; Ruella M
Br J Haematol; 2021 May; 193(3):449-465. PubMed ID: 33222167
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
Salaroli A; Spilleboudt C; Bron D; Lewalle P
Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
[TBL] [Abstract][Full Text] [Related]
19. Preliminary outcomes reported from three randomized controlled trials of CD19 CAR-T cell therapies in large B cell lymphoma.
Jain MD
Mol Ther; 2022 Jan; 30(1):14-16. PubMed ID: 34921770
[No Abstract] [Full Text] [Related]
20. CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
Shargian L; Raanani P; Yeshurun M; Gafter-Gvili A; Gurion R
Br J Haematol; 2023 Jan; 200(1):e4-e5. PubMed ID: 36281746
[No Abstract] [Full Text] [Related]
[Next] [New Search]